MRNA
NASDAQModerna Inc.
Website
News25/Ratings12
News · 26 weeks84-20%
2025-10-262026-04-19
Mix4490d
- Market18(41%)
- Insider12(27%)
- Other7(16%)
- SEC Filings5(11%)
- Analyst1(2%)
- Leadership1(2%)
Latest news
25 items- NEWSModerna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine CandidatePhase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participants in the U.S. and UK have been dosed in a Phase 3 study of the Company's investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. In December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna announced that CEPI will invest up to $54.3 million to help advance mRNA-1018 to licensure."H5 influenza, or bird flu, remains a pandemic threat. The start of our Phase 3 trial fo
- NEWSModerna Announces Data to be Presented at 2026 ASCO Annual MeetingModerna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDTCAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 - June 2 in Chicago, IL.The presentation details are as follows:Oral Presentation:Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 studySession Type/Title: Oral Abstract Session - Melanoma/Skin CancersData & Time:
- NEWSModerna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will be made available in the European Union, subject to national regulatory and access procedures CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX® (mRNA-1083), the Company's mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older.This marketing authorization follows the positive opinion from the European Medi
- NEWSModerna to Present at Upcoming Conferences in May 2026CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:BofA Securities 2026 Healthcare Conference, on Tuesday, May 12th at 11:20am PTRBC 2026 Global Healthcare Conference, on Tuesday, May 19th at 10:00 am ETBernstein's 42nd Annual Strategic Decisions Conference, Thursday, May 28th at 10:00am ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaMod
- NEWSModerna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual MeetingThe U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS>1%)CAMBRIDGE, MA / ACCESS Newswire / April 17, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, on April 17-22, 2026. The presentation reports safety, efficacy and translational data from a Phase 2 dose-expansion cohort of the Phase 1/2 study (NCT05533697), which evaluated mRNA-4359 + pembrol
- NEWSModerna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its first quarter 2026 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a pioneer and leader in the field of mRNA medicine. Through the advancement o
- NEWSModerna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026.Moderna's presentation, "Sequential administration of an mRNA-based seasonal influenza vaccine in older adults," details an exploratory, post-hoc analysis assessing the safety and immunogenicity of mRNA-1010 in adults 50 years
- INSIDERSEC Form 4 filed by Mock James M4 - Moderna, Inc. (0001682852) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.SCHEDULE 13G/A - Moderna, Inc. (0001682852) (Subject)
- SECSEC Form DEF 14A filed by Moderna Inc.DEF 14A - Moderna, Inc. (0001682852) (Filer)
- SECSEC Form DEFA14A filed by Moderna Inc.DEFA14A - Moderna, Inc. (0001682852) (Filer)
- INSIDERChief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 10% to 65,782 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 12% to 56,998 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Bancel Stephane4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERPresident Hoge Stephen converted options into 39,830 shares and covered exercise/tax liability with 19,260 shares, increasing direct ownership by 1% to 1,477,997 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- INSIDERChief Legal Officer Klinger Shannon Thyme exercised 23,884 shares at a strike of $18.00, covered exercise/tax liability with 4,837 shares and sold $726,047 worth of shares (13,885 units at $52.29), increasing direct ownership by 9% to 59,689 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- NEWSModerna Resolves Global Patent Litigation with Arbutus/GenevantModerna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026District Court's Section 1498 decision to be appealed to the Federal Circuit Court of Appeals with potential additional payment contingent on the outcome; no accrual recorded for potential additional payment as loss is not considered probable2026 year-end cash and cash equivalents now expected to be in the range of $4.5 - $5.0 billionCAMBRIDGE, MA / ACCESS Newswire / March 3, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has entered into a settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH resolving all litigation worldwid
- INSIDERChief Financial Officer Mock James M converted options into 11,004 shares and covered exercise/tax liability with 5,323 shares, increasing direct ownership by 13% to 50,905 units (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- NEWSEuropean Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive CHMP opinionmCOMBRIAX will be made available in the European Union, subject to final European Commission authorization and national regulatory and access proceduresCAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union for mCOMBRIAX® (mRNA-1083), Moderna's co
- INSIDERPresident Hoge Stephen exercised 160,009 shares at a strike of $19.15 and sold $7,814,840 worth of shares (160,009 units at $48.84) (SEC Form 4)4 - Moderna, Inc. (0001682852) (Issuer)
- PRTectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the BoardWATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo
- SECSEC Form S-8 filed by Moderna Inc.S-8 - Moderna, Inc. (0001682852) (Filer)
- SECSEC Form 10-K filed by Moderna Inc.10-K - Moderna, Inc. (0001682852) (Filer)
- NEWSModerna to Present at Upcoming Conferences in March 2026CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:TD Cowen 46th Annual Healthcare Conference, on Tuesday, March 3rd at 1:50pm ETBarclays 28th Annual Global Healthcare Conference, on Tuesday, March 10th at 9:30am ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a pioneer and leader in the field of mRNA medicine. Th
- NEWSModerna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine SubmissionFollowing a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to reviewModerna has received a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that, in response to a prior Refusal-to-File (RTF) letter, the Company engaged with the U.S. Food and Drug Administration (FDA) in a Type A meeting and proposed a revised regulatory approach for its investigational seasonal influenza vaccine candidate, mRNA-1010. To advance the review, Moderna proposed a regulatory pathwa